{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
INN:aguracingene cadoparvovec [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:rivunatpagene miziparvovec [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT03116113: Phase 1/Phase 2 Interventional Completed X-Linked Retinitis Pigmentosa
(2017)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:zaftuclenegene piruparvovec [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:alvamemugene sulseparvovec [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT03652259: Phase 1/Phase 2 Interventional Active, not recruiting Limb-Girdle Muscular Dystrophy, Type 2E
(2018)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:patidistrogene bexoparvovec [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT03061201: Phase 2 Interventional Completed Hemophilia A
(2017)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:zocaglusagene nuzaparvovec [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
USAN:COBNABEXAGENE ANVUPARVOVEC HEXB [USAN]
Source URL:
Class:
STRUCTURALLY DIVERSE